Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|August 27, 2026

The BioPharm Brief: Survival, Fast Track, and Tezspire

Listen
0:00 / 0:00

Today’s BioPharm Brief covers positive Phase 3 data for Akeso’s ivonescimab in biliary tract cancer, FDA Fast Track designation for CytomX’s Varseta-M in colorectal cancer, and positive Phase 3 results for Tezspire in eosinophilic esophagitis.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Here are the stories we’re looking at today.

First, Akeso’s ivonescimab has beaten durvalumab on overall survival in a Phase 3 biliary tract cancer trial. The company reported that the bispecific antibody significantly improved overall survival compared with durvalumab in patients with advanced or metastatic biliary tract cancer. The result comes from a head-to-head Phase 3 study and adds to the clinical development of ivonescimab, which is designed to simultaneously target PD-1 and VEGF. Full data are expected to provide more detail on the magnitude of the survival benefit and the treatment’s safety profile.

Next, CytomX’s Varseta-M has received FDA Fast Track designation for relapsed or refractory metastatic colorectal cancer. The investigational antibody-drug conjugate targets EpCAM using CytomX’s PROBODY platform and delivers a topoisomerase-1 inhibitor payload. In Phase 1 data, Varseta-M produced a 32% confirmed response rate at the 10-mg/kg dose, with an 88% disease control rate across the expansion cohort. CytomX plans to begin a potential registrational trial in the first half of 2027.

And Tezspire has met both co-primary endpoints in a Phase 3 trial of eosinophilic esophagitis. In the 368-patient CROSSING study, tezepelumab significantly improved both histologic remission and dysphagia symptoms at week 24, with those improvements sustained through week 52. The anti-TSLP monoclonal antibody is already approved for severe asthma and chronic rhinosinusitis with nasal polyps, making EoE the latest indication in its broader development program. Full results are expected to be presented at an upcoming medical meeting.

That’s The BioPharm Brief for today. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways:

  • Ivonescimab delivers a Phase 3 overall-survival win against durvalumab in biliary tract cancer.
  • CytomX’s Varseta-M earns FDA Fast Track designation after encouraging Phase 1 colorectal cancer data.
  • Tezspire meets both phase 3 endpoints in eosinophilic esophagitis, with benefits sustained through 52 weeks.

Related to this article

View more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more